Management of pilomyxoid astrocytomas: our experience
Hitoshi Tsugu, Shinya Oshiro, Fumio Yanai, Fuminari Komatsu, Hiroshi Abe, Takeo Fukushima, Yuko Nomura, Shinji Matsumoto, Kazuki Nabeshima, Koichi Takano, Hidetsuna Utsunomiya, Hitoshi Tsugu, Shinya Oshiro, Fumio Yanai, Fuminari Komatsu, Hiroshi Abe, Takeo Fukushima, Yuko Nomura, Shinji Matsumoto, Kazuki Nabeshima, Koichi Takano, Hidetsuna Utsunomiya
Abstract
Background: Pilomyxoid astrocytoma (PMA) shows a higher rate of recurrence and cerebrospinal fluid (CSF) dissemination than does pilocytic astrocytoma (PA). In this article, we discuss the treatment of PMA.
Materials and methods: Between 1992 and 2007, the authors treated 5 patients. Two of these were male, three female. Their ages ranged from 3 months to 11 years.
Results: Three patients showed CSF dissemination on the initial radiographic examination. All patients received chemotherapy; the most commonly used combination drugs were cisplatin (CDDP)/carboplatin (CBDCA) and etoposide. When these drugs were unsuccessful, they were changed or other drugs added to the combination. After chemotherapy, four patients showed remarkable tumor regression. Nevertheless, one patient died 22 months after initial diagnosis, due to tumor progression.
Conclusion: While our series was limited to a small number of patients, we have a positive impression of the value of chemotherapy. Even if initial chemotherapy is ineffective, we recommend continued CDDP/CBDCA-based chemotherapy with new drug combinations.
Source: PubMed